LETTER

Anti-TNF- for treatment of amyloidosis associated with Crohn’s disease

A Fernández-Nebro¹, I Ureña², M V Irigoyen², R García-Vicuña³

¹ Servicio de Reumatología, Pabellón "Hospital Civil", Hospital Regional Universitario Carlos Haya, Málaga, Spain
² Servicio de Reumatología, Hospital Regional Universitario Carlos Haya, Málaga, Spain
³ Servicio de Reumatología, Hospital Universitario La Princesa, Madrid, Spain

Correspondence to:
Correspondence to:
Dr A Fernández-Nebro
Servicio de Reumatología, Pabellón "Hospital Civil", Hospital Regional Universitario Carlos Haya, Plaza del Hospital Civil s/n, 29009 Málaga, Spain; afernandezn@uma.es

Keywords: amyloidosis; Crohn’s disease; spondylarthropathy; anti-tumour necrosis factor

The first 150 words of the full text of this article appear below.

We wish to comment on the case reported by Iizuka and colleagues (Gut 2006;55:744–5) of a patient who experienced a reduction in creatine levels from 4 to 2 mg/dl after three weeks of treatment with infliximab for amyloidosis associated with Crohn’s disease. Unfortunately, no details were provided of other concomitant factors, such as volume depletion or drugs, which may have affected baseline creatinine levels and their later course, irrespective of amyloidosis, or of the results of proteinuria observed in 1992.

In our experience,¹ anti-TNF- therapy has a rapid effect on proteinuria but not on renal function. In our patients it took several months (the most rapid decrease was from 1.6 to 0.94 mg/dl in three months) for serum creatinine levels to decrease by (mean (SD) percentage since baseline) 8.5 (16.6)% (range –21.4 to 39.4) after 70 (44) weeks (range 2–120), and only 36% of patients experienced a . . . [Full text of this article]

S Konno⁴, M Iizuka⁴, Y Horie⁴, H Itou⁴, K Shindo⁴, S Watanabe⁴

⁴ Department of Internal Medicine, Akita University School of Medicine, Akita, Japan

Correspondence to:
Correspondence to:
Dr M Iizuka
Department of Internal Medicine, Akita University School of Medicine, 1-1-1 Hondo, Akita 010-8543, Japan; maiizuka@doc.med.akita-u.ac.jp

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

Relevant Article

Infliximab as a treatment for systemic amyloidosis associated with Crohn’s disease

M Iizuka, S Konno, Y Horie, H Itou, K Shindo, and S Watanabe
Gut 2006 55: 744-745. [Extract] [Full Text] [PDF]